Showing 801-810 of 7651 results for "".
Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and Conditions
https://practicaldermatology.com/topics/feature/developing-core-outcome-sets-importance-common-standards-clinical-studies-specific-diseases-and-conditions/26654/Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and ConditionsA Highly Effective Topical Compounded Medication for the Treatment of Cutaneous Warts
https://practicaldermatology.com/topics/general-topics/a-highly-effective-topical-compounded-medication-for-the-treatment-of-cutaneous-warts/20583/A compounded formulation with an adhesive vehicle shows promise for one of the most common and frustrating conditions to treat in dermatology.Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Topical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.Teledermatology Use during the COVID-19 Pandemic
https://practicaldermatology.com/columns/clinical-focus-1/teledermatology-use-during-the-covid-19-pandemic/23769/Despite challenges, the future of teledermatology is promising.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinUpdates in Vitamin D and Sunscreens: Coronavirus and More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/updates-in-vitamin-d-and-sunscreens-coronavirus-and-more/23450/A review of the latest findings regarding vitamin D deficiency, its possible link to COVID-19 severity, and advances in sunscreen formulation.Scientifically Speaking: Sunscreen Update from Terri Michele, MD of the FDA CDER
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-sunscreen-update-from-terri-michele-md-of-the-fda-cder/19853/What is the latest on sunscreen labeling? What are implications of recent serology studies? And could new screening agents come to the US market? Host Joel L. Cohen, MD talks to Terri Michele, MD, Director of the Office of Nonprescription Drugs in FDA CDER about these and other hot topics in sun pro